DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model (Q39329856)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

1 reference

based on heuristic

inferred from title

author name string

Haihong Zhang

1

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Yuqian Wang

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Chenlu Liu

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Lixing Zhang

4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Qiu Xia

5

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Yong Zhang

6

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Jiaxin Wu

7

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Chunlai Jiang

8

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Yan Chen

9

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Yongge Wu

10

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Xiao Zha

11

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Xianghui Yu

12

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Wei Kong

13

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

publication date

17 June 2012

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

61

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

1857-1867

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

https://scigraph.springernature.com/pub.10.1007/s00262-012-1296-3

0 references

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1296-3

21 January 2018

Improvement of different vaccine delivery systems for cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1296-3

21 January 2018

Survivin, cancer networks and pathway-directed drug discovery.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1296-3

21 January 2018

Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1296-3

21 January 2018

Efficient co-transduction of adenoviral vectors encoding carcinoembryonic antigen and survivin into dendritic cells by the CAR-TAT adaptor molecule enhance anti-tumor immunity in a murine colorectal cancer model

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1296-3

21 January 2018

Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1296-3

21 January 2018

Cytokine regulation of natural killer cell effector functions

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1296-3

21 January 2018

Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1296-3

21 January 2018

Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1296-3

21 January 2018

Adenovirus vector-based vaccines for human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1296-3

21 January 2018

Mucosal prior to systemic application of recombinant adenovirus boosting is more immunogenic than systemic application twice but confers similar protection against SIV-challenge in DNA vaccine-primed macaques.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1296-3

21 January 2018

Cancer treatment: the combination of vaccination with other therapies

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1296-3

21 January 2018

A rapid and simple method for the isolation of apoptotic DNA fragments.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1296-3

21 January 2018

Pleiotropic cell-division defects and apoptosis induced by interference with survivin function

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1296-3

21 January 2018

Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1296-3

21 January 2018

Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1296-3

21 January 2018

Detection of autoantibodies to survivin and livin in sera from patients with breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1296-3

21 January 2018

Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1296-3

21 January 2018

Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1296-3

21 January 2018

Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1296-3

21 January 2018

Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1296-3

21 January 2018

Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1296-3

21 January 2018

Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1296-3

21 January 2018

Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1296-3

21 January 2018

Crystal structure of human survivin reveals a bow tie-shaped dimer with two unusual alpha-helical extensions

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1296-3

21 January 2018

Survivin structure: crystal unclear.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1296-3

21 January 2018

Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1296-3

21 January 2018

Identifiers

10.1007/S00262-012-1296-3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39329856&oldid=1820259200"